These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 6568935)

  • 1. Dexamethasone: pharmacokinetics in neurological patients.
    Eadie MJ; Brophy TR; Ohlrich G; Tyrer JH
    Clin Exp Neurol; 1984; 20():107-18. PubMed ID: 6568935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients.
    Brophy TR; McCafferty J; Tyrer JH; Eadie MJ
    Eur J Clin Pharmacol; 1983; 24(1):103-8. PubMed ID: 6832191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients.
    Chalk JB; Ridgeway K; Brophy T; Yelland JD; Eadie MJ
    J Neurol Neurosurg Psychiatry; 1984 Oct; 47(10):1087-90. PubMed ID: 6502166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
    Nakade S; Ohno T; Kitagawa J; Hashimoto Y; Katayama M; Awata H; Kodama Y; Miyata Y
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):75-83. PubMed ID: 18317761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of dexamethasone and its effect on adrenal gland function in the dog.
    Toutain PL; Alvinerie M; Ruckebusch Y
    Am J Vet Res; 1983 Feb; 44(2):212-7. PubMed ID: 6830010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma concentrations of praziquantel during the therapy of neurocysticerosis with praziquantel, in the presence of antiepileptics and dexamethasone.
    Na-Bangchang K; Vanijanonta S; Karbwang J
    Southeast Asian J Trop Med Public Health; 1995 Mar; 26(1):120-3. PubMed ID: 8525397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma.
    McNiel NO; Morgan LR
    Int J Clin Pharmacol Ther Toxicol; 1981 Nov; 19(11):490-3. PubMed ID: 7298241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
    Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
    Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
    Varis T; Kivistö KT; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chlorpropamide bioavailability and pharmacokinetics.
    Huupponen R; Lammintausta R
    Int J Clin Pharmacol Ther Toxicol; 1981 Jul; 19(7):331-3. PubMed ID: 7263111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability and pharmacokinetics of D-penicillamine.
    Kukovetz WR; Beubler E; Kreuzig F; Moritz AJ; Nirnberger G; Werner-Breitenecker L
    J Rheumatol; 1983 Feb; 10(1):90-4. PubMed ID: 6842492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
    Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data.
    Battino D; Croci D; Mamoli D; Messina S; Perucca E
    Epilepsy Res; 2004; 59(2-3):155-65. PubMed ID: 15246117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of vincristine sulfate in adult cancer patients.
    Sethi VS; Jackson DV; White DR; Richards F; Stuart JJ; Muss HB; Cooper MR; Spurr CL
    Cancer Res; 1981 Sep; 41(9 Pt 1):3551-5. PubMed ID: 7260915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pharmacokinetics of clodronate after single and repeated doses.
    Ylitalo P; Holli K; Mönkkönen J; Elo HA; Juhakoski A; Liukko-Sipi S; Ylitalo R
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):294-300. PubMed ID: 10395121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.